(function(){var loadHandler=window['sl_{31D5DFE0-0AD4-4192-A7B3-CC2FCD4AAB43}'];loadHandler&&loadHandler(17, '<div id="spr0_69a682"><div id="spr1_69a682" class="kern"><img id="img2_69a682" src="data/img45.png" width="959px" height="540px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_69a682" class="kern"><div id="spr3_69a682" style="left:111.291px;top:88.605px;"><div id="spr4_69a682"><img id="img0_69a682" src="data/img72.png" width="733.682" height="381.345" alt=""/></div><div id="spr5_69a682" style="top:-0px;"><div style="width:0px;"><span id="txt0_69a682" class="relpos" style="left:10.5px;top:1.35px;">Variables</span></div></div><div id="spr6_69a682" style="left:422.118px;top:0px;"><div style="width:0px;"><span id="txt1_69a682" class="relpos" style="left:91.642px;top:1.334px;">Patients (n=11)</span></div></div><div id="spr7_69a682" style="top:27.217px;"><div style="width:0px;"><span id="txt2_69a682" class="relpos" style="left:5.394px;top:6.905px;">Technical success, n (%)</span></div></div><div id="spr8_69a682" style="left:422.118px;top:27.217px;"><div style="width:0px;"><span id="txt3_69a682" class="relpos" style="left:122.056px;top:6.905px;">11 (100)</span></div></div><div id="spr9_69a682" style="top:65.543px;"><div style="width:0px;"><span id="txt4_69a682" class="relpos" style="left:5.394px;top:1.35px;">Total bilirubin, median (range), mg/dL</span></div></div><div id="spr10_69a682" style="left:424.619px;top:65.543px;"><div style="width:0px;"><span id="txt5_69a682" class="relpos" style="left:153.283px;top:1.35px;"> </span></div></div><div id="spr11_69a682" style="left:0px;top:92.76px;"><div style="width:0px;"><span id="txt6_69a682" class="relpos" style="left:15.385px;top:1.88px;">    Admission</span></div><div style="width:0px;"><span id="txt7_69a682" class="relpos" style="left:15.385px;top:27.554px;">   1 week after RFA</span></div><div style="width:0px;"><span id="txt8_69a682" class="relpos" style="left:15.385px;top:51.927px;">   4 weeks after RFA</span></div></div><div id="spr12_69a682" style="left:422.118px;top:92.76px;"><div style="width:0px;"><span id="txt9_69a682" class="relpos" style="left:100.893px;top:1.88px;">5.8 (2.8-32.1)</span></div><div style="width:0px;"><span id="txt10_69a682" class="relpos" style="left:105.889px;top:27.554px;">2.4 (0.6-8.0)</span></div><div style="width:0px;"><span id="txt11_69a682" class="relpos" style="left:105.889px;top:51.927px;">1.1 (0.5-4.7)</span></div></div><div id="spr13_69a682" style="top:169.782px;"><div style="width:0px;"><span id="txt12_69a682" class="relpos" style="left:5.394px;top:1.88px;">ID-RFA related early adverse events, n (%)</span></div><div style="width:0px;"><span id="txt13_69a682" class="relpos" style="left:5.394px;top:27.554px;">      </span><span id="txt14_69a682" class="relpos" style="left:5.389px;top:27.554px;">perforation / hemobilia  / cholangitis</span></div><div style="width:0px;"><span id="txt15_69a682" class="relpos" style="left:5.394px;top:53.228px;">      </span><span id="txt16_69a682" class="relpos" style="left:5.389px;top:53.228px;">pancreatitis &amp;</span><span id="txt17_69a682" class="relpos" style="left:5.384px;top:53.228px;"> fever</span></div><div style="width:0px;"><span id="txt18_69a682" class="relpos" style="left:5.394px;top:77.601px;">      fever only</span></div></div><div id="spr14_69a682" style="left:422.118px;top:169.782px;"><div style="width:0px;"><span id="txt19_69a682" class="relpos" style="left:82.972px;top:27.554px;">0 (0) / 0 (0) / 0 (0)</span></div><div style="width:0px;"><span id="txt20_69a682" class="relpos" style="left:129.18px;top:53.228px;">1 (9.1)</span></div><div style="width:0px;"><span id="txt21_69a682" class="relpos" style="left:124.185px;top:77.601px;">5 (45.5)</span></div></div><div id="spr15_69a682" style="top:272.478px;"><div style="width:0px;"><span id="txt22_69a682" class="relpos" style="left:5.394px;top:1.35px;">Total follow up duration, median (range), d</span></div></div><div id="spr16_69a682" style="left:422.118px;top:272.478px;"><div style="width:0px;"><span id="txt23_69a682" class="relpos" style="left:101.705px;top:1.35px;">98 (30 – 207)</span></div></div><div id="spr17_69a682" style="top:299.695px;"><div style="width:0px;"><span id="txt24_69a682" class="relpos" style="left:5.394px;top:1.35px;">      30 days stent patency, n (%)</span></div></div><div id="spr18_69a682" style="left:422.118px;top:299.695px;"><div style="width:0px;"><span id="txt25_69a682" class="relpos" style="left:122.056px;top:1.35px;">11 (100)</span></div></div><div id="spr19_69a682" style="top:326.912px;"><div style="width:0px;"><span id="txt26_69a682" class="relpos" style="left:5.394px;top:1.368px;">      S</span><span id="txt27_69a682" class="relpos" style="left:5.389px;top:1.368px;">tent occlusion</span><span id="txt28_69a682" class="relpos" style="left:5.384px;top:1.119px;">*</span><span id="txt29_69a682" class="relpos" style="left:5.379px;top:1.368px;">, n (%)</span></div></div><div id="spr20_69a682" style="left:422.118px;top:326.912px;"><div style="width:0px;"><span id="txt30_69a682" class="relpos" style="left:124.185px;top:1.35px;">3 </span><span id="txt31_69a682" class="relpos" style="left:124.18px;top:1.35px;">(27.3)</span></div></div><div id="spr21_69a682" style="top:354.128px;"><div style="width:0px;"><span id="txt32_69a682" class="relpos" style="left:5.394px;top:1.368px;">      Mortality during follow up period</span><span id="txt33_69a682" class="relpos" style="left:5.389px;top:1.119px;">*</span><span id="txt34_69a682" class="relpos" style="left:5.384px;top:1.368px;">, n (%)</span></div></div><div id="spr22_69a682" style="left:422.118px;top:354.128px;"><div style="width:0px;"><span id="txt35_69a682" class="relpos" style="left:124.185px;top:1.35px;">2 (18.2)</span></div></div></div><div id="spr23_69a682" style="left:338px;top:28px;"><img id="img1_69a682" src="data/img73.png" width="282" height="31" alt="Clinical outcomes"/></div><div id="spr24_69a682" style="left:111.291px;top:479.739px;"><div style="width:0px;"><span id="txt36_69a682" class="relpos" style="left:7.193px;top:4.558px;">* Overall survival was 151 and 191 days for each case.</span></div><div style="width:0px;"><span id="txt37_69a682" class="relpos" style="left:7.193px;top:26.153px;">Median event-free survival was 91 days.</span></div></div><div id="spr25_69a682" style="left:713.796px;top:489.521px;"><div style="width:0px;"><span id="txt38_69a682" style="left:12.271px;top:2.109px;">Kim EJ et al. EIO 2019, in press</span></div></div></div></div>');})();